High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey

Table 3 Comparisons of HDL-cholesterol levels in the three antipsychotic groups with stratification by BMI for outpatients

			Olanzapine	Risperidone	Aripiprazole	p-value
HDL-cholesterol	BMI < 18.5	mg/dL	72.1 ± 18.7 (8)	81.3 ± 30.4 (4)	62.5 ± 3.4 (4)	0.959
	18.5 ≤ BMI < 25	mg/dL	57.6 ± 13.4 (69)	61.4 ± 23.0 (96)	60.7 ± 17.7 (45)	0.442
	BMI ≥ 25	mg/dL	53.0 ± 15.6 (61)	52.7 ± 15.8 (94)	51.9 ± 18.4 (52)	0.819

Data are shown as the mean ± SD (number of subjects)
Analyses of covariance among the three antipsychotics were performed for HDL-cholesterol with age, diastolic blood pressure, chlorpromazine-equivalent dosage and waist circumference as confounding variables
Post-hoc analyses were performed by the Bonferroni method
HDL high-density lipoprotein, BMI body mass index

ISSN: 1471-244X